Search research articles
Contact Us
Filters
Showing results (71-80 of 414) with videos related to
Page
of 42
Sort By:
European Journal of Immunology
|
April 1, 1994
gld/gld mice are unable to express a functional ligand for Fas
F Ramsdell, M S Seaman, R E Miller, et al.
International Immunology
|
October 1, 1994
Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death
F Ramsdell, M S Seaman, R E Miller, et al.
Plos One
|
December 7, 2013
Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data
Andrew L Ferguson, Emilia Falkowska, Laura M Walker, et al.
Journal of Virology
|
March 2, 2012
Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma
Mohammad M Sajadi, George K Lewis, Michael S Seaman, et al.
Journal of Virology
|
July 31, 2009
Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens
Sandrine L Hulot, Michael S Seaman, Pritha Sen, et al.
Mucosal Immunology
|
December 15, 2016
Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity
V Lorin, M Malbec, C Eden, et al.
Mucosal Immunology
|
April 25, 2017
Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity
V Lorin, M Malbec, C Eden, et al.
AIDS Research and Human Retroviruses
|
July 8, 2015
Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C
Yehuda Z Cohen, Christy L Lavine, Caroline A Miller, et al.
AIDS (London, England)
|
December 24, 2013
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Peter Hraber, Michael S Seaman, Robert T Bailer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 2, 2012
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope
Craig S Pace, Marshall W Fordyce, David Franco, et al.
Page
of 42
Search research articles
Search
Showing results (71-80 of 414) with videos related to
Sort By:
Page
of 42
European Journal of Immunology
|
April 1, 1994
gld/gld mice are unable to express a functional ligand for Fas
F Ramsdell, M S Seaman, R E Miller, et al.
International Immunology
|
October 1, 1994
Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death
F Ramsdell, M S Seaman, R E Miller, et al.
Plos One
|
December 7, 2013
Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data
Andrew L Ferguson, Emilia Falkowska, Laura M Walker, et al.
Journal of Virology
|
March 2, 2012
Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma
Mohammad M Sajadi, George K Lewis, Michael S Seaman, et al.
Journal of Virology
|
July 31, 2009
Diverse cross-reactive potential and Vbeta gene usage of an epitope-specific cytotoxic T-lymphocyte population in monkeys immunized with diverse human immunodeficiency virus type 1 Env immunogens
Sandrine L Hulot, Michael S Seaman, Pritha Sen, et al.
Mucosal Immunology
|
December 15, 2016
Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity
V Lorin, M Malbec, C Eden, et al.
Mucosal Immunology
|
April 25, 2017
Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity
V Lorin, M Malbec, C Eden, et al.
AIDS Research and Human Retroviruses
|
July 8, 2015
Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C
Yehuda Z Cohen, Christy L Lavine, Caroline A Miller, et al.
AIDS (London, England)
|
December 24, 2013
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Peter Hraber, Michael S Seaman, Robert T Bailer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 2, 2012
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope
Craig S Pace, Marshall W Fordyce, David Franco, et al.
Page
of 42